Published • loading... • Updated
NICE Approves Teplizumab for Early-Stage Type 1 Diabetes on NHS
The one-time immunotherapy can delay symptomatic type 1 diabetes by nearly three years, NICE said, giving patients more time before insulin treatment is needed.
- The National Institute for Health and Care Excellence approved Teplizumab for NHS use in England and Wales, marking a "landmark" moment for early-stage type 1 diabetes treatment.
- Known as Tzield, the immunotherapy trains the immune system to stop attacking pancreatic cells, delaying symptomatic type 1 diabetes by an average of nearly three years.
- Administered via a 14-day daily infusion, the treatment is approved for patients aged eight and over who are in the early stages before symptoms appear.
- NICE estimates around 1,100 people could be eligible in the first year, with approximately 820 patients annually thereafter, offering families precious extra time without insulin management.
- While The Early Surveillance for Autoimmune Diabetes and T1DRA studies screen eligible patients, NICE guidance does not apply in Northern Ireland; the Scottish Medicines Consortium expects advice by early 2027.
Insights by Ground AI
19 Articles
19 Articles
Type 1 diabetes drug that can delay diagnosis by YEARS approved for NHS patients as health chiefs hail 'incredible moment'
A type 1 diabetes drug that can delay diagnosis by three years has been approved for use by NHS patients, in what health chiefs have hailed as an "incredible moment".The National Institute for Health and Care Excellence has granted approval for teplizumab, marking the most significant advancement in type 1 diabetes treatment in over a century.The immunotherapy, which can postpone the emergence of symptomatic diabetes by up to three years, will n…
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources19
Leaning Left2Leaning Right2Center10Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
